This 2004 NEJM review by Roodman examines the molecular and cellular mechanisms driving bone metastasis across cancer types. It asks why bone is such a preferred metastatic site and how osteolytic versus osteoblastic lesion patterns arise from dysregulated tumor-bone crosstalk. It synthesizes the evidence on RANKL/OPG signaling, the PTHrP-driven vicious circle in breast cancer, and the unique biology of myeloma bone disease.
When a patient with multiple myeloma has severe bone pain but a normal bone scan, do not be falsely reassured. Myeloma's purely lytic lesions generate no reactive bone formation — the scan has nothing to detect. Plain radiographs and skeletal survey remain the standard imaging approach.
When you see a patient with metastatic breast or prostate cancer and skeletal-related events (fracture, hypercalcemia, cord compression), the underlying driver is osteoclast activation. Not direct tumor invasion of cortical bone. This is why bisphosphonates and RANKL inhibitors (denosumab) are disease-modifying, not just palliative.
The RANKL/osteoprotegerin axis is the central target in bone metastasis pharmacology. Denosumab (anti-RANKL antibody) was developed directly from the biology described in this review, and its superiority over bisphosphonates in preventing skeletal-related events is the downstream clinical validation of this mechanism.
For the boards: osteoblastic metastasis does NOT mean bone resorption is absent. Prostate cancer bone metastases are predominantly osteoblastic yet still show elevated resorption markers. Bisphosphonates reduce skeletal events in prostate cancer for exactly this reason.
This 2004 NEJM review by Roodman examines the molecular and cellular mechanisms driving bone metastasis across cancer types. It asks why bone is such a preferred metastatic site and how osteolytic versus osteoblastic lesion patterns arise from dysregulated tumor-bone crosstalk. It synthesizes the evidence on RANKL/OPG signaling, the PTHrP-driven vicious circle in breast cancer, and the unique biology of myeloma bone disease.
When a patient with multiple myeloma has severe bone pain but a normal bone scan, do not be falsely reassured. Myeloma's purely lytic lesions generate no reactive bone formation — the scan has nothing to detect. Plain radiographs and skeletal survey remain the standard imaging approach.
When you see a patient with metastatic breast or prostate cancer and skeletal-related events (fracture, hypercalcemia, cord compression), the underlying driver is osteoclast activation. Not direct tumor invasion of cortical bone. This is why bisphosphonates and RANKL inhibitors (denosumab) are disease-modifying, not just palliative.
The RANKL/osteoprotegerin axis is the central target in bone metastasis pharmacology. Denosumab (anti-RANKL antibody) was developed directly from the biology described in this review, and its superiority over bisphosphonates in preventing skeletal-related events is the downstream clinical validation of this mechanism.
For the boards: osteoblastic metastasis does NOT mean bone resorption is absent. Prostate cancer bone metastases are predominantly osteoblastic yet still show elevated resorption markers. Bisphosphonates reduce skeletal events in prostate cancer for exactly this reason.